Benitec Biopharma reported full-year fiscal 2026 results and provided clinical and regulatory updates for BB-301, its investigational genetic medicine for Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagia. All six patients in Cohort 1, which received low-dose BB-301, completed the full 12-month post-treatment follow-up, while Cohort 2 was fully enrolled with all three patients safely treated. A Type C meeting with the U.S. Food and Drug Administration was held in the third quarter of 2026 to discuss the pivotal study design, with meeting minutes anticipated in October. Interim results from the ongoing Phase 1b/2a study were accepted for a late-breaking presentation at the European Society of Gene and Cell Therapy congress in Hamburg from October 27 to 30, 2026. The company reported clinically meaningful improvements in patient-reported swallowing symptoms and X-ray-based swallowing assessments, alongside a favorable safety profile. Benitec said it anticipates initiating the BB-301 pivotal trial in mid-2027. For fiscal 2026, total operating expenses rose to $51.2 million from $41.8 million, while net loss attributable to shareholders was $45.5 million, or $0.98 per basic and diluted share. Cash and cash equivalents totaled $180.0 million as of June 30, 2026.